ArticleThe Journal of infectious diseases2019
Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Formal Comment on "Platelet-leucocyte interactions drive MMP-mediated tissue damage in tuberculosis" (Kirwan et al., 2026).PLoS pathogens · 2026Article
- Integration of transcriptome and mendelian randomization elucidates the protective role of aspirin in pulmonary tuberculosis development.Functional & integrative genomics · 2026Article
- Loss of 7-Dehydrocholesterol Reductase mediated cholesterol biosynthesis activates IRF3 and inhibits control ofbioRxiv : the preprint server for biology · 2026Article
- The inflammasome adaptor pycard is essential for immunity against Mycobacterium marinum infection in adult zebrafish.Disease models & mechanisms · 2025Article
- Article
- OXSR1 inhibits inflammasome activation by limiting potassium efflux during mycobacterial infection.Life science alliance · 2022Article
- Inhibition of infection-induced vascular permeability modulates host leukocyte recruitment to Mycobacterium marinum granulomas in zebrafish.Pathogens and disease · 2022Article
- A fresh look at mycobacterial pathogenicity with the zebrafish host model.Molecular microbiology · 2022Review
- Article
- Host-directed therapy to combat mycobacterial infections.Immunological reviews · 2021Review
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- Platelet Activation and the Immune Response to Tuberculosis.Frontiers in immunology · 2021Review
- Conserved anti-inflammatory effects and sensing of butyrate in zebrafish.Gut microbes · 2020Article
- Zebrafish as a Model for Fish Diseases in Aquaculture.Pathogens (Basel, Switzerland) · 2020Review
- Illuminating Macrophage Contributions to Host-Pathogen InteractionsInfection and immunity · 2020Review
- Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundInfection-induced thrombocytosis is a clinically important complication of tuberculosis infection. Recent studies have highlighted the utility of aspirin as a host-directed therapy modulating the inflammatory response to infection but have not investigated the possibility that the effect of aspirin is related to an antiplatelet mode of action.
methodsIn this study, we utilize the zebrafish-Mycobacterium marinum model to show mycobacteria drive host hemostasis through the formation of granulomas. Treatment of infected zebrafish with aspirin markedly reduced mycobacterial burden. This effect is reproduced by treatment with platelet-specific glycoprotein IIb/IIIa inhibitors demonstrating a detrimental role for infection-induced thrombocyte activation.
resultsWe find that the reduction in mycobacterial burden is dependent on macrophages and granuloma formation, providing the first in vivo experimental evidence that infection-induced platelet activation compromises protective host immunity to mycobacterial infection.
conclusionsOur study illuminates platelet activation as an efficacious target of aspirin, a widely available and affordable host-directed therapy candidate for tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.